Background-The use of hormone replacement therapy (HRT) is prevalent in the age group invited to routine breast cancer screening in many countries. Previous publications have reported reduced sensitivity and specificity of mammographic breast cancer screening associated with current use of HRT. Objectives-To review the epidemiological evidence for the relation between use of HRT and the risk of having breast cancer diagnosed between screens (interval breast cancer-sensitivity) and being recalled for assessment after initial mammography with no diagnosis of breast cancer at that screen (false positive recall-specificity). Methods-Overview of published literature. Results-Eight studies were identified, providing a total of 367 interval cancers and 8878 cases of false positive recall, in women of 50 and over. Overall, the studies showed an increased risk of interval cancer and false positive recall in current users of HRT compared with non-users. Only one study accounted for the essential confounding factors of age and menopause. Furthermore, information on duration and recency of HRT use was not available for most studies. Conclusions-Studies to date indicate that women using HRT are more likely to experience reduced sensitivity and specificity of breast cancer screening, compared with women not using HRT. However, because results have not been adjusted for crucial confounding factors, the magnitude of these eVects is uncertain. (J Med Screen 2001;8:29-35) Keywords: hormone replacement therapy; mammography; breast screening; interval cancer Hormone replacement therapy (HRT) refers to the use of estrogen or its analogues, with or without progestogen, primarily for the treatment of menopausal symptoms. Use of HRT has increased rapidly in recent years and is particularly prevalent in the age group invited to routine breast cancer screening in many countries.
Hormone replacement therapy (HRT) refers to the use of estrogen or its analogues, with or without progestogen, primarily for the treatment of menopausal symptoms. Use of HRT has increased rapidly in recent years and is particularly prevalent in the age group invited to routine breast cancer screening in many countries. 1 In a recent survey of women attending the United Kingdom NHS breast screening programme 33% were found to be currently using HRT and 14% were found to be past users. 2 Mammographic screening is an important intervention for the early detection of breast cancer, and the ability of a screening programme to detect breast cancer at an early stage relates closely to its ability to reduce breast cancer mortality in the long term. There is evidence that women who are currently using HRT are more likely than non-users to have breast cancer which presents in the interval between screens (interval cancer). Users of HRT may therefore not experience the same benefit from screening, in terms of a reduction in breast cancer mortality, as non-users. Previous publications have also shown that, compared with non-users, women who are currently using HRT may experience more false positive recall, whereby they are recalled for assessment after initial mammography, but are subsequently found not to have breast cancer. The frequency of false positive recall is important in terms of the psychological, physical, and financial cost of a screening programme.
This article aims to provide a summary of the evidence to date on the eVect of use of HRT on the risk of interval cancer and the risk of false positive recall after mammographic screening for breast cancer.
Methods
Epidemiological studies providing original data on the relation between HRT and the sensitivity (risk of interval cancer) or specificity (risk of false positive recall) of mammographic breast cancer screening published up to the end of January 2000 were identified through searches of Medline and the Science Citation Index. This was supplemented by searches of reference lists in identified papers and hand searches of relevant journals. No restriction was placed on study size or language of publication and no attempt was made to identify unpublished studies or unpublished data from published reports.
STATISTICAL METHODS
Due to the diVerences in the measures of the eVect of HRT on screening given in each study, the crude published figures on the numbers of women screened, screen detected cancers, interval cancers, and false positive recalls according to the use of HRT, were abstracted for each study when available. The diagnosis of breast cancer was taken as that presented in each study; some included both ductal carcinoma in situ and invasive breast cancer, whereas others excluded ductal carcinoma in situ (discussed later). Sensitivity was calculated as the percentage of total cancers (interval plus screen detected) which were detected at screening, based on the assumption that most interval cancers (particularly those occurring early in the screening interval) were present and missed at screening. Specificity was the percentage of women without breast cancer (neither interval nor screen detected cancer) who were screen negative, which is broadly equal to 100% minus the percentage who had false positive recall. A true negative screen was defined as a negative screen with no subsequent interval cancer.
To present data in a uniform manner from various studies about the relation between use of HRT and screening eVectiveness, indices relating to the eVect of HRT on sensitivity and specificity were obtained. The index relating to sensitivity was taken as the relative proportion of breast cancers which presented as interval cancers (interval cancer/(interval cancer+screen detected cancer)) in current users of HRT versus non-users. This is essentially the relative proportion of women classified as disease negative at screening among those who were ultimately shown to have breast cancer. The index relating to specificity was the relative proportion of women who did not have breast cancer who experienced a false positive screen (false positives/(false positives+true negatives)) in current users of HRT versus non-users. This is essentially the relative proportion of women who were classified as disease positive at screening among those who were ultimately shown not to have breast cancer.
To make the results of the studies more comparable, only data from women aged 50 and older were included in the figures. Where possible, data on interval cancer were limited to a 1 year interval. Where results were presented separately by screening round, crude relative proportions for the first and subsequent rounds were calculated, then combined as a weighted average to provide an overall relative proportion, adjusted for screening round. With these criteria, adjusted figures from the published studies were used where possible, otherwise crude relative proportions were calculated with the data abstracted from each publication. For one study, crude data for the appropriate interval and age group were back calculated using the published figures for sensitivity. 3 The relative proportion for the measure of eVectiveness for each study is indicated in the figures by the position of the black squares, the area of which is proportional to the amount of statistical information (proportional to the inverse of the variance of the log of relative proportion). The horizontal lines on either side of the squares represent the 95% confidence intervals (95% CIs) around the relative proportions. The method of empirically weighted least squares was used to test for heterogeneity between the relative proportions shown in each figure. 4 The scales used diVer between the two figures. No summary estimates of risk were calculated due to the limitations of the published data (see later).
Results
Eight studies were identified; three reported on HRT and interval cancer risk only, [5] [6] [7] four reported on the risk of both interval cancer and false positive recall, 3 8-10 and one reported on recall only. 11 Many screening programmes collect information on current use of HRT at the time of mammography, often to aid the radiologist in interpretation of the film. The published studies tended to use this routinely collected data, and the information relating to use of HRT was therefore mainly in the form of current versus non-current use (never and past users were combined). Data on the relation between past use of HRT, duration of use, and screening eVectiveness were therefore limited, and little information on potential confounding factors was available.
SENSITIVITY, RISK OF INTERVAL CANCER, AND USE OF HRT
There were seven published studies directly examining the relation between HRT and the sensitivity of mammography (table 1) . 3 5-10 Studies were conducted in five diVerent countries and involved relatively few interval cancers in users of HRT. In women not using HRT the rate of screen detected cancer was 4.0-8.7/1000 women screened and the interval cancer rate was 0.3-1.1/year/1000 women screened. Sensitivity varied by study, screening round, and duration of interval. In all but one study, 9 sensitivity was substantially lower in current users of HRT than in non-users.
Two studies included only invasive breast cancer, three included both invasive cancer and ductal carcinoma in situ and the remaining two studies did not state any histological inclusion criteria (table 1). As ductal carcinoma in situ rarely presents symptomatically, its inclusion will tend to increase numbers of screen detected cancers but not interval cancers. These diVering inclusion criteria should not aVect measures of mammographic sensitivity to any great extent, as the number of ductal carcinomas in situ would be added to both the numerator and the denominator of the percentage, and ductal carcinoma in situ makes up about 20% of screen detected cancers. 12 For similar reasons, the varying inclusion of ductal carcinoma in situ is unlikely to have a large eVect on the relative proportion of interval versus screen detected cancer in users of HRT compared with non-users. Figure 1 provides a graphical summary of the studies and presents the relative proportion of breast cancers diagnosed as interval cancers among women of 50 and over, for current users of HRT compared with never users of HRT 8 9 or to women not currently using HRT. 3 6 7 10 All but one of the studies showed a substantial increase in the risk of interval cancer compared with screen detected cancer in current users of HRT, although there was significant heterogeneity between study results (p<0.05). The study which did not find an association between use of HRT and risk of interval cancer was relatively small and used diVerent screening methods dependent on mammographic density. 9 Although results are restricted to women of 50 and over, the lack of adjustment for potential confounding factors such as age, menopause, and time since menopause should be borne in mind when interpreting these data.
No studies presented information on the relation between duration of use of HRT and interval cancer. Only two studies contained information on the eVect of past use of HRT on the risk of having an interval cancer, providing a total of two interval cancers in past users and 11 in never users (table 1). 8 9 Given these very small numbers, no statistical comparison of the risk of interval cancer in past and never users of HRT was attempted. Adjusted for screening round using published data. Previously screened women only. Two studies included women under 50, and when these women were excluded, the association between use of HRT and the risk of first year interval cancer in each individual study strengthened. The crude relative proportion (calculated from published data) for interval versus total cancer in current users of HRT versus women not currently using HRT went from a mean (95% CI) of 1.4 (1.1 to 1.9) to 1.7 (1.2 to 2.4) in the study of Rosenberg et al, 6 when data from women under 50 were excluded. In Kavanagh et al, 3 the result for women of 40 and over was 1.9 (1.2 to 3.1) and when data were restricted to women 50-69 it was 2.5 (1.4 to 4.5). In keeping with this, based on small numbers, neither study found any significant eVect of current use of HRT on risk of interval cancer in women under 50.
SPECIFICITY, FALSE POSITIVE RECALL, AND USE OF HRT
A total of five studies that investigated the relation between use of HRT and mammographic specificity or the risk of false positive recall were identified 3 8-11 (table 2) . Among women who were not using HRT, the percentage of false positive recall varied markedly by study, from 2.1% among previously screened women attending the United Kingdom NHS breast screening programme, 11 to 14.7% overall in a programme in the United States. 8 All studies found some evidence of lower specificity in current users of HRT compared with non-users; in three studies this overall association was significant (table 2) . 3 8 9 This result is shown graphically in figure 2, based on a total of 2451 cases of false positive recall in current users of HRT and 6427 cases in non-users. No significant heterogeneity was found between the study results (p>0.1). Only one of these studies was able to account for menopausal status, none were able to control for other reproductive factors, and most did not adjust for age.
One study provided information on specificity according to duration of use of HRT. In current users of <3 , 3-6, and >6 years' duration, Thurfjell et al, 9 reported specificities of 95%, 95%, and 92% respectively (p=0.046). Based on published data, the test for trend in false positive recall with increasing duration of use of HRT was of borderline significance ( 2 =3.3, p=0.07, my calculations). Two studies had information on false positive recall in past users of HRT, compared with women who had never used HRT. 8 9 In both studies there was no significant diVerence in recall in former users compared with never users, based on a 
Discussion
In studies published to date, current users of HRT experienced a substantially higher risk of interval cancer and somewhat higher risk of false positive recall at mammography than women who were not using HRT. The lack of adjustment for crucial confounding factors such as age and the menopause, the choice of control group, and the lack of accounting for diVerent durations of use of HRT means that the overall magnitude of the association between use of HRT and specificity and sensitivity of screening is uncertain. The published studies have important limitations. The total number of interval cancers was relatively small. Age is strongly related to current use of HRT 13 and to the incidence of interval cancer.
14 As, compared with older women, younger women are more likely to be premenopausal and experience a lower sensitivity at mammography and are generally not using HRT, the lack of accounting for age and menopausal status (in all but one of the studies) is likely to result in an underestimation of the eVect of HRT. This is supported by the fact that in studies where women under 50 (who are more likely to be premenopausal) were originally included, the eVect of HRT strengthened when they were excluded. The eVect of other possible confounding factors, such as reproductive or demographic variables, is diYcult to estimate due to the lack of information on their eVect on sensitivity. Furthermore, data from past and never users of HRT were combined to form the non-exposed comparison group in most studies, and if any eVect of use of HRT persists after the end of use, this could further attenuate the measured eVect of HRT. Data on many important aspects of use of HRT were limited. Specifically, data on the eVects of duration of use, time since last use, type of HRT (combined therapy or estrogen alone), and dose of HRT are lacking. Such data are important in the characterisation and measurement of any eVect of HRT.
Studies have tended to present their results as crude odds ratios (or relative risks) of diVerent outcomes, rather than as rates relevant to the overall study population, which are generally more informative and less prone to distortion by variations in one outcome relative to another. For example, an increase in the odds ratio for interval cancer versus screen detected cancer can be the result of an increase in the rate of interval cancer or a decrease in the rate of screen detected cancer, or a combination of the two. Future studies should ideally include some consideration of rates of interval cancer, screen detected cancer, and false positive recall.
The possibility that the results shown here could be aVected by various kinds of bias cannot be excluded. In particular, issues surrounding the selective publication of positive results should always be considered in a review of this nature. It has also been suggested that increased medical surveillance among women receiving HRT, rather than decreased sensitivity, could be responsible for their increased risk of interval cancer. 10 However, any diVerence in surveillance is unlikely to account for a substantial proportion of the excess of first year interval cancers, for several reasons. The relative excess of first year interval cancers among current users of HRT in the published studies is an order of magnitude greater (figure 1) than the excess incidence of breast cancer among current users of HRT compared with non-users in the general population (for example, the bulk of the available data shows that current use of HRT is associated with an increase in the risk of breast cancer of 2.3% per year of use 15 ). Interval cancers occurring in the first year after screening are generally symptomatic. The women involved in the studies were suYciently health conscious to attend for breast cancer screening and it seems unlikely that there would be a large diVerence between such "breast aware" users of HRT and non-users for detection and investigation of symptomatic breast lesions. Furthermore, most of the data collection in the reviewed studies predated the wider awareness of the relation between use of HRT and breast cancer. 15 Decreased sensitivity rather than increased surveillance is therefore a more plausible explanation for the increase in the risk of first year interval cancer among current users of HRT.
There is supporting evidence to indicate that use of HRT is likely to have a detrimental eVect on sensitivity and specificity of screening. Mammographic breast cancer screening programmes mainly target women aged 50 and over, who are generally postmenopausal. Mammographic screening for younger, predominantly premenopausal women has been characterised by lower sensitivity, specificity, and cost eVectiveness, compared with that for older women. 16 17 It has been hypothesised that the lower eVectiveness of screening in younger women relates to their higher mammographic density, which makes it more diYcult either to detect breast cancer or to reliably exclude its presence. By attenuating the physiological drop in ovarian hormone concentrations at the menopause, hormone replacement therapy can, in theory, be seen to prolong a more premenopausal state of the breast, retaining higher levels of tissue density to palpation and mammography. It has been shown that women who are currently using HRT have a higher proportion of their mammogram occupied by relatively dense tissue than nonusers. [18] [19] [20] It is therefore biologically plausible that use of HRT could adversely aVect the sensitivity and specificity of mammographic screening for breast cancer, possibly through increasing mammographic density.
The likely time to onset and oVset of the eVect of HRT is not known. Mammographic density has been shown to vary over the course of the menstrual cycle 21 and stopping the use of HRT has been shown to lead to regression of some mammographic densities within 2 weeks. 22 This suggests that ovarian hormones can lead to relatively rapid changes in the mammographic appearance of breast tissue, and that some aspects of their eVects could wear oV in a matter of weeks. However, it is not clear whether all of the changes associated with HRT are reversible within this period.
Given the relatively high prevalence of current use of HRT in women attending mammographic screening for breast cancer, the findings have important implications for screening programmes. Several screening programmes have reported rates of interval cancer that are higher than expected on the basis of earlier trials of screening eYcacy. 3 23 Such trials were conducted when use of HRT was uncommon, and for the United Kingdom NHS breast screening programme, it has been shown that use of HRT could explain the diVerence between observed and expected rates of interval cancer. 23 It is therefore possible that the eVectiveness of breast cancer screening in reducing mortality from breast cancer could be compromised by use of HRT.
Being recalled for assessment after initial mammography is a stressful experience for women, 24 and the investigation of false positives accounted for one quarter of the cost of mammographic screening in a United States health maintenance organisation and one fifth of the cost of a screening trial in Stockholm. 17 25 Elmore et al 25 estimated that 49% of United States women who had been screened 10 times would have experienced a false positive screen, and called for measures to reduce false positives. A certain number of false positives is inevitable in a screening programme, and is an inherent part of the screening process. Indeed, if an increased rate of false positive recall were accompanied by increased cancer detection, then increasing recall could be considered appropriate and cost eVective in some settings. However, the current evidence on the total eVect of HRT on screening shows an increase in false positive recall and an increase in interval cancer (suggesting a decrease in detection of cancer). Use of HRT therefore seems to be associated with increased diagnostic uncertainty, both in diYculty with excluding the presence of breast cancer and in diYculty detecting it.
Despite the limitations of the current data, it is likely that the use of HRT results in decreased sensitivity and specificity of mammographic screening for breast cancer. However, the current evidence does not form an adequate basis for changes in screening policy. There is an urgent need for reliable data on the eVect of current use of HRT on the risk of interval cancer and false positive recall, with adequate numbers of cases and the ability to control for important confounding factors. Information on the eVect of duration, dose, and type of HRT is also required and information on tumour size and disease stage would be of interest. Data on the eVect of past use of HRT, and particularly time since last use, would be needed to establish how long any eVect of HRT might take to wear oV. Furthermore, there is a need for additional radiological studies documenting the time to onset and oVset of any eVect of HRT, as well as development of methods to improve the ability to detect breast cancer in women who are currently using HRT. Meanwhile the combination of an increase in the risk of breast cancer in women using HRT 15 with a decrease in the ability to detect it is cause for concern.
